US/UK/Canada

Share

Pick a time period -
Tags ( Active)

PolarCap® to be used by several national teams during the FIFA World Cup

The med-tech company PolarCool AB (publ.) announces that three national teams qualified for the FIFA World Cup 2026 in North America will have access to PolarCap® during the tournament. Treatment with PolarCap® will be included in the teams’ medical protocols for players who suffer a concussion during the tournament. PolarCool’s CEO Erik Andersson comments: -The use of PolarCap® at the world’s biggest football tournament sends a strong signal about the growing importance of early concussion treatment in elite football. We are very proud that several national teams competing at the

Achilles Capital AB (publ.) increases its ownership in PolarCool through the acquisition of 100,000 shares

The med-tech company PolarCool AB (publ.) announces that Achilles Capital AB has purchased an additional 100,000 shares, corresponding to approximately 1% of the company. Following the transaction, Achilles Capital will own approximately 26.5% of the shares in PolarCool. PolarCool’s CEO Erik Andersson comments: -We are glad that our major shareholder Achilles Capital has chosen to acquire an additional 100,000 shares, thereby increasing its ownership in the company. This is a clear vote of confidence in what we are doing and shows that they recognize the company’s significant

PolarCool Completes MDSAP Process Enabling Application for Product Approval in Canada

The med-tech company PolarCool AB (publ.) has received its MDSAP approval (Medical Device Single Audit Program) following the successful completion of Stage 1 and Stage 2 audits conducted by Intertek. The MDSAP process is therefore finalized, and PolarCool can now proceed with the application for market approval of PolarCap® in Canada. The MDSAP approval means that PolarCool as a company is approved to launch products in several markets outside Europe, such as Canada, the United States, and Australia, among others. The approval replaces separate approvals of the company’s quality

PolarCool Signs Agreement in Finland with Ice Hockey Club Ilves

The med-tech company PolarCool AB (publ.) has signed an agreement with Finnish Liiga club Ilves for the implementation of PolarCap® as part of the club’s concussion management protocol. The agreement further strengthens PolarCool’s presence in Finland’s top division, Liiga, where the company already collaborates with Rauman Lukko and KalPa. With Ilves joining, PolarCool now partners with three of the league’s 16 teams. PolarCool maintains a strong market position within professional ice hockey across Europe, with agreements in all major leagues. In addition, the company holds a league-

PolarCool Signs Its Third Agreement in the British Elite Ice Hockey League with Manchester Storm

The med-tech company PolarCool AB (publ.) has entered into an agreement with the professional ice hockey team Manchester Storm in the British Elite Ice Hockey League (EIHL). The club becomes the third team in the league to use PolarCap® for the acute treatment of concussions.   With Manchester Storm as a new customer, PolarCool further expands its presence in the British top league, which consists of a total of ten teams from England, Northern Ireland, Scotland, and Wales. PolarCool already has agreements in place with Cardiff Devils and Sheffield Steelers for the use of PolarCap®.

PolarCool establishes PolarCap® in the British Ice Hockey League with the Cardiff Devils

The med-tech company PolarCool AB (publ.) has signed its first agreement in the British Elite Ice Hockey League (EIHL) with the Cardiff Devils, who will incorporate the PolarCap® System into their concussion management routines. PolarCool develops the product PolarCap®, which alleviates the effects of concussions. The primary customers are sports clubs and facilities in ice hockey, rugby, football, and handball, but also other sports with an increased risk of concussion. PolarCool continues to establish the PolarCap® System successfully in European professional ice hockey. Currently,

BioStock: PolarCool´s CEO on the goals for 2023

2022 has been somewhat of a breakthrough year for medtech company PolarCool and their PolarCap System, a medical cooling device intended to reduce concussion symptoms and improve recovery after a head injury. The company advanced on several fronts. Not only did new scientific data clinically confirm the technology's positive effect, but the company also entered into several agreements and received orders from elite sport clubs. BioStock contacted CEO Erik Andersson for a comment on the progress made during 2022, and the goals for 2023.Read the interview with Erik Andersson at biostock.se:

BioStock: PolarCool’s concussion treatment used by Wales at World Cup

The knockout stages of the 2022 FIFA World Cup are underway, yet the controversy around the treatment of concussions at the tournament has been swirling since the opening group stages. Despite an early exit for the Welsh team from the tournament, their medical team took important steps during the campaign to protect their players. Thanks to a partnership between the Football Association of Wales and Swedish MedTech company PolarCool, Welsh players had access to PolarCool’s PolarCap System – a medical cooling device intended to reduce concussion symptoms and improve recovery after a head

BioStock: PolarCool boosted by 5-year clinical study results

Medtech company PolarCool has developed PolarCap, a medical device that actively cools down the brain in the acute phase of an injury to decrease concussion symptoms. Results from a 5-year clinical study with the device have just been published in the Journal of Neurotrauma, and PolarCool’s CEO Erik Andersson stopped by the BioStock Studio to discuss the results.Watch the interview with PolarCool's CEO Erik Andersson at biostock.se: https://www.biostock.se/en/2022/10/polarcool-boosted-by-5-year-clinical-study-results/This is a press release from BioStock - Connecting Innovation &

BioStock: PolarCool’s CEO sees increased demand for PolarCap

In an effort to bring its concussion treatment device to new markets around Europe, PolarCool has recently reached key agreements in Germany, the UK, and Finland. The company’s CEO Erik Andersson believes their business strategy will hasten their journey towards break-even. Read the full Q&A below.Read the interview with Erik Andersson at biostock.se: https://www.biostock.se/en/2022/09/polarcools-ceo-sees-increased-demand-for-polarcap/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Swedish Hockey League taking concussion treatment seriously

Concussions are a serious, yet too often, underestimated issue in ice hockey. However, over the last few years, the Swedish Hockey League has been taking steps to give this problem more attention in the name of player safety, including the adoption of PolarCool’s concussion treatment PolarCap. BioStock reached out to IF Malmö Redhawks defenseman Markus Lauridsen to get a player’s perspective on the handling of concussions by the league and why PolarCap could be a gamechanger.Read the interview with Markus Lauridsen at biostock.se: Swedish Hockey League taking concussion treatment

BioStock: Köping Hockey Chairman puts player safety first

Köping Hockey is a third tier ice hockey team in Sweden, and its players do not get the same benefits as those in top league, the SHL. However, Köping chairman Anders Näsström strongly believes in player safety, and has thus invested in PolarCool’s brain cooling device PolarCap for concussion treatment. BioStock reached out to Näsström to get his take.Read the interview with Anders Näsström at biostock.se: https://www.biostock.se/en/2022/07/koping-hockeys-ordforande-satter-spelarnas-sakerhet-forst/This is a press release from BioStock - Connecting Innovation & Capital. https://www.

BioStock: PolarCool’s strategy for international expansion

As new deals made by Swedish medical device company PolarCool continue to pile on, it is quite clear that the company’s marketing strategy is working. A major contributing factor comes from the recent recruitment of Jamie Bache, now PolarCool’s Head of Sports Marketing. BioStock reached out to Jamie for an in-depth overview of his role.Read the interview with Jamie Bache at biostock.se: https://www.biostock.se/en/2022/06/polarcools-strategi-for-internationell-expansion/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: PolarCool Q4 performance improved in 2021

PolarCool’s Q4 report reflects the significant investments made in clinical validation of its concussion treatment device, PolarCap System. Those investments starting to pay off as net sales during the period have doubled compared to the same period last year. PolarCool expects those numbers to continue to increase in the months to come as more licensing agreements are made. BioStock spoke with CEO Erik Andersson to get his take.Read the interview with Erik Andersson at biostock.se : https://www.biostock.se/en/2022/02/polarcool-q4-performance-improved-in-2021/

BioStock: PolarCool expands market potential with new investment

PolarCool has announced joining forces with BrainCool's subsidiary CoolPrevent to invest in new, more cost-effective and patentable products for single use that enable the treatment of whiplash injuries but also in the area of rehab. This investment gives PolarCool, which continues to grow its market share through new deals regarding the use of its braincooling device PolarCap, the potential to expand its market even further.Read the interview with Erik Andersson at biostock.se : https://www.biostock.se/en/2022/02/polarcool-expands-market-potential-with-new-

BioStock: PolarCool’s breakthrough year in 2021

In 2021, PolarCool took large strides in its ambition to bring its brain cooling device PolarCap System to new markets. After positive clinical validation efforts, PolarCool has greatly expanded its European market presence within a wide range of professional sports and is now eyeing the US. BioStock got in touch with PolarCool’s CEO Erik Andersson to hear how he evaluates 2021 and what 2022 will shape up to look like for the company.Read the interview with Erik Andersson at biostock.se : https://www.biostock.se/en/2022/01/polarcools-breakthrough-year-in-2021/

BioStock: Stade Français signs commercial deal with PolarCool

For medtech company PolarCool, autumn has been marked by a flurry of activity surrounding its medical cooling device PolarCap System. This has resulted in a number of deals with sports teams, among others the French rugby club Stade Français that signed a six-week evaluation deal in September. On Monday, PolarCool announced that, following a successful evaluation period, Stade Français have now signed a two-year commercial deal for PolarCap System.Read the full article at biostock.se: https://www.biostock.se/en/2021/12/stade-francais-signs-commercial-deal-with-polarcool/ This is a

BioStock: PolarCool sees potential in the US as competition grows

With the ambition to continue riding the wave of positive momentum, PolarCool recently raised 5 MSEK in a directed share issue to invest in further market expansion. As the company eyes the single largest market for medtech devices, the USA, competitor TecTraum’s pro2cool concussion treatment device recently received Breakthrough Device Designation from the FDA. BioStock got in touch with PolarCool’s CEO Erik Andersson to get his thoughts on the developments overseas and what it means for PolarCool’s ambitions.Read the interview with Erik Andersson at biostock.se :

BioStock: PolarCool enters English Premier League market

PolarCool’s brain cooling device for treating concussions, PolarCap System, continues to make to breakthroughs in new markets. This week, the Swedish medtech company has announced signing an agreement with the English Premier League club Leeds United, thus entering what is arguably the most recognised sports league in the world.Read the article at biostock.se : https://www.biostock.se/en/2021/11/polarcool-enters-english-premier-league-market/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se 

BioStock: PolarCap provided during IFAF European final

PolarCool’s brain cooling device PolarCap System for treating concussions is quickly gaining popularity across different sports and top leagues across Europe. Most recently, the device was used during the American Football European Championship final, where Sweden played against Italy. To learn more about how the device was introduced to the Swedish national team, BioStock got in touch with PolarCool’s Service and Delivery Manager Eric Rennermalm, who is responsible for establishing PolarCap in Sweden.Read the interview with Eric Rennermalm at biostock.se: https://www.biostock.se/en/2021/

BioStock: PolarCool’s presence in France gets local media boost

Between September and October, PolarCool signed two six-week evaluation agreements to introduce its brain cooling device PolarCap in France. Both agreements are with top-league ruby teams within the country. The local media sees the transactions as an important development for French Rugby, which has seen the amount of head injuries increase in recent years.Read the article at biostock.se : https://www.biostock.se/en/2021/11/polarcools-presence-in-france-gets-local-media-boost/ This is a press release from BioStock - Connecting Innovation & Capital. https:/

BioStock: PolarCool expands market share in France

After signing an initial 6-week evaluation agreement with French rugby team Stade Français to introduce PolarCap in France, PolarCool has signed its second evaluation agreement in France. This time the counterpart is Biarritz Olympique Pays Basque, another team from Top14, the highest league in French rugby.Read the article at biostock.se : https://www.biostock.se/en/2021/10/polarcool-expands-market-share-in-france/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se 

BioStock: PolarCool makes breakthrough in Swiss market

Lately, PolarCool’s cooling method for treating concussions, the PolarCap System, has been gaining traction internationally. Last month, the company signed an agreement with the French Rugby team Stade Français, and, this week, a two-year commercial agreement was signed with the Swiss ice hockey team HC Davos.Read the article at biostock.se: https://www.biostock.se/en/2021/10/polarcool-makes-breakthrough-in-swiss-market/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se 

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe